Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

News SummaryMost relevantAll newsSector newsTweets 

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

share with twitter share with LinkedIn share with facebook
share via e-mail
05/14/2012 | 06:55pm CET

--FDA concludes safety review of MS drug Gilenya

--FDA advises against use in certain heart and stroke patients

--FDA says no clear link between Gilenya and cardiovascular deaths

(Updates with additional background on EMA review starting in seventh paragraph and information on experimental Biogen Idec MS drug.)

   By Jennifer Corbett Dooren 

The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.

The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.

The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily.

As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear."

The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines.

Europe's drug regulator, the European Medicines Agency, last month requested stronger safety warnings for Gilenya after the agency concluded its review of the drug.

Gilenya is currently the only oral MS drug on the market but its sales prospects have been clouded by recent safety concerns. It was approved in the U.S. in 2010 and has been available in Europe since 2011.

The product is designed to treat patients with the relapsing form of MS, which is a progressive disease that involves damage to the nerves controlling muscles and vision.

The FDA is currently reviewing another oral MS drug from Biogen Idec Inc. (BIIB) called BG-12 that is designed to work through a different mechanism than Gilenya. Biogen Idec last week announced that the FDA accepted BG-12's new drug application for a standard 10-month review, which sets an agency decision deadline of about Dec. 28.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
01/18 Drugmakers in Davos shift focus to chronic diseases of poor
01/16 NOVARTIS : invests in next generation therapies to reduce cardiovascular risk in..
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/13 NOVARTIS : NICE approves kidney cancer drug for NHS use
01/12 NOVARTIS : "Combination Therapy Comprising an Inhibitor of Jak, Cdk, and Pim" in..
01/12 NOVARTIS : Patent Issued for Pharmaceutical Combination Comprising a Phosphatidy..
01/09 IONIS PHARMACEUTICALS : Novartis invests in next generation therapies to reduce ..
01/09 NOVARTIS AG : Blog Coverage Novartis Joins Hands with Ionis Pharma For Cardiovas..
01/09 MOMENTA PHARMACEUTICALS,INC. (NASDAQ : MNTA) Files An 8-K Results of Operations ..
01/07 Momenta Provides Year-End 2016 Corporate Update
More news
Sector news : Pharmaceuticals - NEC
08:57a ASTRAZENECA : GSK grabs Astra executive to replace exiting pharma head
08:48aDJBusiness Watch -- WSJ
08:28aDJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave
01/18DJCSL : Expects Higher Profits On Strong Immunoglobulin Sales -- Update
01/18DJCSL : Expects Higher 1st Half Profits On Strong Immunoglobulin Sales
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/18 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2016 Update
01/17 Even A $100M Series A Can't Save The Medtech Venture Climate
01/17 Mast Therapeutics Merges With Savara To Create A Force In Lung/Heart Inhalati..
01/16 PFIZER : 2 Risks Every Shareholder Should Be Aware Of
01/13 U.S. Supreme Court to hear suits over biosimilar approval process
Financials ($)
Sales 2016 48 745 M
EBIT 2016 11 760 M
Net income 2016 7 987 M
Debt 2016 15 019 M
Yield 2016 3,94%
P/E ratio 2016 20,89
P/E ratio 2017 19,89
EV / Sales 2016 4,20x
EV / Sales 2017 4,15x
Capitalization 189 507 M
More Financials
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 29
Average target price 79,7 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-3.71%189 507
JOHNSON & JOHNSON-0.44%312 045
ROCHE HOLDING LTD.1.29%203 230
PFIZER INC.-1.39%194 369
MERCK & CO., INC.3.91%168 654
SANOFI-0.52%105 178
More Results